2022
Intraperitoneal Insulin Delivery: Evidence of a Physiological Route for Artificial Pancreas From Compartmental Modeling
Presti J, Galderisi A, Doyle F, Zisser H, Dassau E, Renard E, Toffanin C, Cobelli C. Intraperitoneal Insulin Delivery: Evidence of a Physiological Route for Artificial Pancreas From Compartmental Modeling. Journal Of Diabetes Science And Technology 2022, 17: 751-756. PMID: 35144503, PMCID: PMC10210098, DOI: 10.1177/19322968221076559.Peer-Reviewed Original ResearchConceptsInsulin deliveryClosed-loop insulin deliveryInsulin kineticsIntraperitoneal insulin deliveryPeripheral hyperinsulinemiaGlycemic controlSubcutaneous routePeritoneal compartmentModel predictive controllerPhysiological routeArtificial pancreasCompartmental modelingDeliveryUVA/Padova T1D simulatorCompartmental modelProportional integral derivative (PID) controllerHyperinsulinemia
2020
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
Galderisi A, Bruschettini M, Russo C, Hall R, Trevisanuto D. Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants. Cochrane Database Of Systematic Reviews 2020, 12: cd013309. PMID: 33348448, PMCID: PMC8092644, DOI: 10.1002/14651858.cd013309.pub2.Peer-Reviewed Original ResearchConceptsPreterm infantsContinuous glucose monitoringGlycemic measuresRisk ratioIntermittent modalitiesLong-term neurodevelopmental impairmentGlucose monitoringCare Group (EPOC) criteriaCochrane Central RegisterCochrane Effective PracticePrevention of morbidityQuasi-randomized trialStandard search strategyClinical trials databasesLong-term outcomesPreterm infant mortalityAllied Health LiteratureUse of CGMImprecision of estimatesFixed-effects modelCochrane NeonatalAdverse neurodevelopmentCentral RegisterGRADE approachControlled Trials
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdults
2016
Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe
Del Favero S, Boscari F, Messori M, Rabbone I, Bonfanti R, Sabbion A, Iafusco D, Schiaffini R, Visentin R, Calore R, Moncada Y, Galasso S, Galderisi A, Vallone V, Di Palma F, Losiouk E, Lanzola G, Tinti D, Rigamonti A, Marigliano M, Zanfardino A, Rapini N, Avogaro A, Chernavvsky D, Magni L, Cobelli C, Bruttomesso D. Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. Diabetes Care 2016, 39: 1180-1185. PMID: 27208335, DOI: 10.2337/dc15-2815.Peer-Reviewed Original ResearchConceptsSensor-augmented pumpCrossover trialMean glucoseArtificial pancreasType 1 diabetesArtificial Pancreas ProjectWearable artificial pancreasAP trialOlder childrenTrialsHypoglycemiaYoung childrenChildrenPancreasOvernight timeSignificant changesGlucoseDaysDiabetesOutpatientsResearch designThreefold reduction